{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T19:28:24Z","timestamp":1793820504717,"version":"4.6.1"},"reference-count":42,"publisher":"American Medical Association (AMA)","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"<jats:sec id=\"ab-zoi241026-4\">\n                    <jats:title>Importance<\/jats:title>\n                    <jats:p>Incidence, prevalence, and survival are pertinent measures to inform the management and provision of prostate cancer care.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-zoi241026-5\">\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To calculate the incidence, prevalence, and survival rates for prostate cancer in the UK from 2000 to 2021.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-zoi241026-6\">\n                    <jats:title>Design, Setting, and Participants<\/jats:title>\n                    <jats:p>This population-based cohort study uses routinely collected primary care data from the UK. Male patients aged 18 years or older with at least 1 year of history registered in Clinical Practice Research Datalink (CPRD) GOLD or Aurum were included. Data were analyzed from January 2023 to March 2024.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-zoi241026-7\">\n                    <jats:title>Main Outcomes and Measures<\/jats:title>\n                    <jats:p>Prostate cancer incidence rates (IR), period prevalence (PP), and 1-, 5-, and 10-year survival after diagnosis between 2000 and 2021, stratified by age and calendar years.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-zoi241026-8\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>This study included 64\u202f925 and 133\u202f200 patients with prostate cancer in CPRD GOLD and Aurum, respectively, with a median age of 72 (65-78) years. The overall IR of prostate cancer was 151.7 (95% CI, 150.6 to 152.9) per 100\u202f000 person-years in GOLD to 153.1 (95% CI, 152.3 to 153.9) per 100\u202f000 person-years for Aurum and increased with age. The incidence of prostate cancer increased from 109 per 100 000 person-years in 2000 to 159 per 100 000 person-years in 2021. Peaks of incidence occurred in 2004 and 2018, before a decline in 2020. PP increased 3.5 times over the study period for both databases, from 0.4% in 2000 to 1.4% in 2021. IR and PP were highest in those aged 80 to 89 years. Median (95% CI) survival was similar in both databases (GOLD: 10.9 [95% CI, 10.7-11.1] years and Aurum: 11.1 [95% CI, 11.0-11.2] years). Survival at 1, 5, and 10 years after diagnosis were 93.4% (95% CI, 93.2%-93.6%), 71.8% (95% CI, 71.4%-72.2%), 53.2% (95% CI, 52.6%-53.7%) in GOLD and 93.9% (95% CI, 93.7%-94.0%), 72.7% (95% CI, 72.5%-73.0%), 53.7% (95% CI, 53.3%-54.1%) in AURUM, respectively. Survival increased over time: 1-year survival was 94.8% (95% CI, 94.5%-95.2%) in those diagnosed between 2015 to 2019 compared with 90.8% (95% CI, 90.2%-91.3%) from 2000 to 2004; 5-year survival improved from 65.3% (95% CI, 64.4%-66.3%) from 2000 to 2004 to 75.3% (95% CI, 74.4%-76.3%) in 2015 to 2019.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-zoi241026-9\">\n                    <jats:title>Conclusions and Relevance<\/jats:title>\n                    <jats:p>In this population-based cohort study, incidence and prevalence increased with older age, with high survival rates reflecting a high burden of disease, particularly in the management of cancer survivorship in an aging population. Health care systems should consider this when managing the increasing numbers of people with prevalent prostate cancer.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2024.34622","type":"journal-article","created":{"date-parts":[[2024,9,19]],"date-time":"2024-09-19T12:27:04Z","timestamp":1726748824000},"page":"e2434622","source":"Crossref","is-referenced-by-count":24,"title":["Incidence, Prevalence, and Survival of Prostate Cancer in the UK"],"prefix":"10.1001","volume":"7","author":[{"given":"Eng Hooi","family":"Tan","sequence":"first","affiliation":[{"name":"Centre for Statistics in Medicine, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward","family":"Burn","sequence":"additional","affiliation":[{"name":"Centre for Statistics in Medicine, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola L.","family":"Barclay","sequence":"additional","affiliation":[{"name":"Centre for Statistics in Medicine, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonella","family":"Delmestri","sequence":"additional","affiliation":[{"name":"Centre for Statistics in Medicine, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wai Yi","family":"Man","sequence":"additional","affiliation":[{"name":"Centre for Statistics in Medicine, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asieh","family":"Golozar","sequence":"additional","affiliation":[{"name":"Odysseus Data Service, Cambridge, Massachusetts"},{"name":"Observational Health Data Sciences and Informatics Center at the Roux Institute, Northeastern University, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c0lvar Rosell\u00f3","family":"Serrano","sequence":"additional","affiliation":[{"name":"Institut Catal\u00e0 d\u2019Oncologia, Hospital Universitari Dr Josep Trueta, Girona, Catalonia, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Talita","family":"Duarte-Salles","sequence":"additional","affiliation":[{"name":"Fundaci\u00f3 Institut Universitari per a la recerca a l\u2019Atenci\u00f3 Prim\u00e0ria de Salut Jordi Gol i Gurina, Barcelona, Spain"},{"name":"Department of Medical Informatics, Erasmus University Medical Centre, Rotterdam, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip","family":"Cornford","sequence":"additional","affiliation":[{"name":"Liverpool University Hospitals Foundation Trust, Liverpool, United Kingdom"},{"name":"The University of Liverpool, Liverpool, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Prieto Alhambra","sequence":"additional","affiliation":[{"name":"Centre for Statistics in Medicine, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, United Kingdom"},{"name":"Department of Medical Informatics, Erasmus University Medical Centre, Rotterdam, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danielle","family":"Newby","sequence":"additional","affiliation":[{"name":"Centre for Statistics in Medicine, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"OPTIMA Consortium","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2024,9,19]]},"reference":[{"issue":"3","key":"zoi241026r1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global Cancer Statistics 2020: globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries.","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"issue":"9","key":"zoi241026r4","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1016\/j.annonc.2020.06.011","article-title":"Prostate cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.","volume":"31","author":"Parker","year":"2020","journal-title":"Ann Oncol"},{"issue":"3","key":"zoi241026r6","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1093\/ije\/dyv098","article-title":"Data resource profile: Clinical Practice Research Datalink (CPRD).","volume":"44","author":"Herrett","year":"2015","journal-title":"Int J Epidemiol"},{"issue":"6","key":"zoi241026r7","doi-asserted-by":"publisher","first-page":"1740","DOI":"10.1093\/ije\/dyz034","article-title":"Data resource profile: Clinical Practice Research Datalink (CPRD) Aurum.","volume":"48","author":"Wolf","year":"2019","journal-title":"Int J Epidemiol"},{"key":"zoi241026r8","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.canep.2018.08.009","article-title":"Comparison of cancer diagnosis recording between the Clinical Practice Research Datalink, Cancer Registry and Hospital Episodes Statistics.","volume":"57","author":"Arhi","year":"2018","journal-title":"Cancer Epidemiol"},{"issue":"8","key":"zoi241026r13","doi-asserted-by":"publisher","first-page":"573","DOI":"10.7326\/0003-4819-147-8-200710160-00010","article-title":"The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies.","volume":"147","author":"von Elm","year":"2007","journal-title":"Ann Intern Med"},{"issue":"3","key":"zoi241026r14","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1093\/jamia\/ocu023","article-title":"Feasibility and utility of applications of the common data model to multiple, disparate observational health databases.","volume":"22","author":"Voss","year":"2015","journal-title":"J Am Med Inform Assoc"},{"key":"zoi241026r15","first-page":"574","article-title":"Observational Health Data Sciences and Informatics (OHDSI): opportunities for observational researchers.","volume":"216","author":"Hripcsak","year":"2015","journal-title":"Stud Health Technol Inform"},{"issue":"5","key":"zoi241026r16","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1002\/pds.4747","article-title":"The accuracy of date of death recording in the Clinical Practice Research Datalink GOLD database in England compared with the Office for National Statistics death registrations.","volume":"28","author":"Gallagher","year":"2019","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"282","key":"zoi241026r18","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1080\/01621459.1958.10501452","article-title":"Nonparametric estimation from incomplete observations.","volume":"53","author":"Kaplan","year":"1958","journal-title":"J Am Stat Assoc"},{"issue":"3","key":"zoi241026r23","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1038\/s41416-020-0859-x","article-title":"Fatal prostate cancer incidence trends in the United States and England by race, stage, and treatment.","volume":"123","author":"Butler","year":"2020","journal-title":"Br J Cancer"},{"issue":"10","key":"zoi241026r24","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2017-017729","article-title":"Prostate-specific antigen (PSA) testing of men in UK general practice: a 10-year longitudinal cohort study.","volume":"7","author":"Young","year":"2017","journal-title":"BMJ Open"},{"issue":"664","key":"zoi241026r25","doi-asserted-by":"publisher","first-page":"e775","DOI":"10.3399\/bjgp17X693077","article-title":"The role of the quality and outcomes framework in the care of long-term conditions: a systematic review.","volume":"67","author":"Forbes","year":"2017","journal-title":"Br J Gen Pract"},{"issue":"4","key":"zoi241026r26","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1111\/bju.14992","article-title":"Implications of celebrity endorsement of prostate cancer awareness in a tertiary referral unit\u2014the \u2018Fry-Turnbull\u2019 effect.","volume":"125","author":"Lovegrove","year":"2020","journal-title":"BJU Int"},{"issue":"4","key":"zoi241026r27","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1016\/S1470-2045(21)00148-0","article-title":"COVID-19 and cancer: 1 year on.","volume":"22","author":"The Lancet Oncology","year":"2021","journal-title":"Lancet Oncol"},{"issue":"10125","key":"zoi241026r31","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1016\/S0140-6736(17)33326-3","article-title":"Global surveillance of trends in cancer survival 2000-14 (CONCORD-3): analysis of individual records for 37?513?025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries.","volume":"391","author":"Allemani","year":"2018","journal-title":"Lancet"},{"issue":"Suppl 1","key":"zoi241026r32","doi-asserted-by":"publisher","first-page":"S75","DOI":"10.1038\/sj.bjc.6604595","article-title":"Survival from prostate cancer in England and Wales up to 2001.","volume":"99","author":"Rowan","year":"2008","journal-title":"Br J Cancer"},{"issue":"1","key":"zoi241026r33","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.eururo.2019.08.005","article-title":"Recent global patterns in prostate cancer incidence and mortality rates.","volume":"77","author":"Culp","year":"2020","journal-title":"Eur Urol"},{"issue":"9","key":"zoi241026r34","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1001\/jama.2018.0154","article-title":"Effect of a low-intensity psa-based screening intervention on prostate cancer mortality: the CAP randomized clinical trial.","volume":"319","author":"Martin","year":"2018","journal-title":"JAMA"},{"issue":"17","key":"zoi241026r35","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1056\/NEJMoa2214122","article-title":"Fifteen-year outcomes after monitoring, surgery, or radiotherapy for prostate cancer.","volume":"388","author":"Hamdy","year":"2023","journal-title":"N Engl J Med"},{"issue":"2","key":"zoi241026r36","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/j.eururo.2020.09.042","article-title":"EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer-2020 Update. Part 1: screening, diagnosis, and local treatment with curative intent.","volume":"79","author":"Mottet","year":"2021","journal-title":"Eur Urol"},{"issue":"2","key":"zoi241026r38","doi-asserted-by":"publisher","first-page":"461","DOI":"10.3390\/cancers15020461","article-title":"Metastatic prostate cancer-a review of current treatment options and promising new approaches.","volume":"15","author":"Posdzich","year":"2023","journal-title":"Cancers (Basel)"},{"issue":"8","key":"zoi241026r39","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1007\/s10552-016-0780-z","article-title":"Estimating the prevalence of hematological malignancies and precursor conditions using data from Haematological Malignancy Research Network (HMRN).","volume":"27","author":"Li","year":"2016","journal-title":"Cancer Causes Control"},{"issue":"1","key":"zoi241026r40","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1186\/s12874-022-01632-7","article-title":"A systematic review of methods to estimate colorectal cancer incidence using population-based cancer registries.","volume":"22","author":"Alsadhan","year":"2022","journal-title":"BMC Med Res Methodol"},{"issue":"1","key":"zoi241026r41","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1093\/ije\/dyz076","article-title":"Data resource profile: National Cancer Registration Dataset in England.","volume":"49","author":"Henson","year":"2020","journal-title":"Int J Epidemiol"},{"issue":"8","key":"zoi241026r42","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2020-037719","article-title":"What are the implications of using individual and combined sources of routinely collected data to identify and characterise incident site-specific cancers? a concordance and validation study using linked English electronic health records data.","volume":"10","author":"Strongman","year":"2020","journal-title":"BMJ Open"},{"key":"zoi241026r2","unstructured":"NICE Clinical Knowledge Summaries. What should I advise about screening for prostate cancer? National Institute for Health Care Excellence. Accessed August 13, 2024. https:\/\/cks.nice.org.uk\/topics\/prostate-cancer\/diagnosis\/screening-for-prostate-cancer\/"},{"key":"zoi241026r3","unstructured":"Prostate cancer risk management programme: overview. Public Health England. Accessed August 13, 2024. https:\/\/www.gov.uk\/guidance\/prostate-cancer-risk-management-programme-overview"},{"key":"zoi241026r5","unstructured":"NHS England. Checks for prostate cancer hit all-time high on back of NHS and charity awareness campaign. National Health Service. Accessed January 4, 2024. https:\/\/www.england.nhs.uk\/2022\/05\/checks-for-prostate-cancer-hit-all-time-high-on-back-of-nhs-and-charity-awareness-campaign\/"},{"key":"zoi241026r9","unstructured":"National Cancer Registration and Analysis Service. Cancer Incidence and Mortality. Accessed August 13, 2024. https:\/\/www.cancerdata.nhs.uk\/incidence_and_mortality"},{"key":"zoi241026r10","unstructured":"Cancer incidence in Scotland\u2014cancer incidence and prevalence in Scotland to December 2019. Public Health Scotland. Accessed August 13, 2024. https:\/\/publichealthscotland.scot\/publications\/cancer-incidence-in-scotland\/cancer-incidence-in-scotland-cancer-incidence-and-prevalence-in-scotland-to-december-2019"},{"key":"zoi241026r11","unstructured":"Cancer Incidence in Wales, 2002-2019. Public Health Wales. Accessed August 13, 2024. https:\/\/phw.nhs.wales\/services-and-teams\/"},{"key":"zoi241026r12","unstructured":"Prostate cancer statistics: 1993-2020. Northern Ireland Cancer Registry. Accessed August 13, 2024. https:\/\/www.qub.ac.uk\/research-centres\/nicr\/CancerInformation\/official-statistics\/BySite\/Prostatecancer\/"},{"key":"zoi241026r17","unstructured":"Revision of the European Standard Population: Report of Eurostat\u2019s Taskforce\u20142013 edition. Eurostat. Accessed August 13, 2024. https:\/\/ec.europa.eu\/eurostat\/en\/web\/products-manuals-and-guidelines\/-\/ks-ra-13-028"},{"key":"zoi241026r19","unstructured":"Incidence and prevalence of different cancers. Github. Accessed August 13, 2024. https:\/\/github.com\/oxford-pharmacoepi\/EHDENCancerIncidencePrevalence"},{"key":"zoi241026r20","doi-asserted-by":"crossref","unstructured":"Incidence, Prevalence and Survival of Prostate Cancer in the United Kingdom between 2000 and 2021. Accessed August 13, 2024. https:\/\/dpa-pde-oxford.shinyapps.io\/ProstateCancerIncPrevSurvShiny\/","DOI":"10.21037\/tlcr-24-241"},{"key":"zoi241026r21","unstructured":"CPRD GOLD June 2022 dataset. Accessed August 13, 2024. https:\/\/www.cprd.com\/cprd-gold-june-2022-dataset"},{"key":"zoi241026r22","unstructured":"Suspected cancer: recognition and referral. National Institute for Health and Care Excellence. Accessed August 13, 2024. https:\/\/www.nice.org.uk\/guidance\/ng12"},{"key":"zoi241026r28","doi-asserted-by":"crossref","unstructured":"Barclay? NL, Moncus\u00ed? MP, J\u00f6dicke? AM, . The impact of the UK COVID-19 lockdown on the screening, diagnostics and incidence of breast, colorectal, lung and prostate cancer in the UK: a population-based cohort study.? medRxiv. 2023. Preprint posted online September 13, 2023. doi:10.1101\/2023.07.21.23292937","DOI":"10.3389\/fonc.2024.1370862"},{"key":"zoi241026r29","unstructured":"Cancer survival in England\u2014adults diagnosed. Office for National Statistics. Accessed August 13, 2024. https:\/\/www.ons.gov.uk\/peoplepopulationandcommunity\/healthandsocialcare\/conditionsanddiseases\/datasets\/cancersurvivalratescancersurvivalinenglandadultsdiagnosed"},{"key":"zoi241026r30","unstructured":"National life tables\u2014life expectancy in the UK: 2018 to 2020. Office for National Statistics. Accessed August 30, 2024. https:\/\/www.ons.gov.uk\/peoplepopulationandcommunity\/birthsdeathsandmarriages\/lifeexpectancies\/bulletins\/nationallifetablesunitedkingdom\/2018to2020#life-expectancy-at-older-ages"},{"key":"zoi241026r37","unstructured":"Department of Health and Social Care. Biggest prostate cancer screening trial in decades to start in UK. Accessed January 27, 2024. https:\/\/www.gov.uk\/government\/news\/biggest-prostate-cancer-screening-trial-in-decades-to-start-in-uk"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2823751\/tan_2024_oi_241026_1725981924.90632.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,28]],"date-time":"2024-11-28T07:11:56Z","timestamp":1732777916000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2823751"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,19]]},"references-count":42,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2024,9,3]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2024.34622","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,19]]}}}